Benign prostatic hyperplasia: symptoms, diagnosis and treatment overview

Summary

In this eight‑minute presentation, Dr. Paulien Moyaert outlines the pathophysiology of BPH, emphasizing the role of androgen‑driven stromal and epithelial cell proliferation within the peri‑urethral zone of the prostate. She explains how hormonal changes with age, particularly dihydrotestosterone, contribute to gland enlargement and subsequent urinary outflow obstruction. The video then enumerates common clinical manifestations such as nocturia, weak stream, and incomplete bladder emptying, noting the variability in symptom severity among patients. Diagnostic strategies are reviewed, including the importance of a thorough history, digital rectal examination, urinalysis to exclude infection, and the use of uroflowmetry and post‑void residual measurement. Dr. Moyaert also mentions the role of prostate‑specific antigen (PSA) testing for risk stratification, while cautioning that PSA elevation alone does not confirm BPH. Therapeutic options are categorized into watchful waiting, pharmacologic therapy, and surgical interventions. First‑line medications such as alpha‑adrenergic antagonists and 5‑alpha‑reductase inhibitors are described, with a brief discussion of their mechanisms, benefits, and typical side‑effects. Indications for minimally invasive procedures (e.g., transurethral microwave therapy) and definitive surgery (e.g., transurethral resection of the prostate) are outlined, highlighting patient‑specific factors that guide treatment choice. The presenter concludes by emphasizing the importance of individualized care, regular monitoring of symptom progression, and shared decision‑making between clinicians and patients. She underscores that while BPH is a common, benign condition, it can significantly impact quality of life if left unmanaged. Overall, the video serves as a rapid, academically oriented primer on BPH, suitable for medical students preparing for exams or clinical rotations in urology.

Key Takeaways

• ✓BPH results from age‑related hormonal influences that cause prostate tissue growth, leading to urinary obstruction.
• ✓Typical symptoms include increased urinary frequency, nocturia, weak stream, and a sensation of incomplete bladder emptying.
• ✓Diagnosis relies on history, physical exam, urine testing, uroflowmetry, and may include PSA measurement for risk assessment.
• ✓First‑line pharmacologic treatments are alpha‑blockers and 5‑alpha‑reductase inhibitors, each with distinct side‑effect profiles.
• ✓Surgical or minimally invasive procedures are reserved for patients with refractory symptoms or complications.

What to Be Careful About

• ⚠The video does not replace clinical consultation; individual patient evaluation is essential.
• ⚠Medication side‑effects and surgical risks are briefly mentioned and should be discussed in detail with a healthcare provider.

Topics

Key terms in this video

Related reviews

• Many Men Chose The Wrong Prostate Cancer Treatment: Here’s WhyThe Prostate Clinic
• Shrink ENLARGED PROSTATE in 7 Easy Steps (2026 confirmation)KenDBerryMD
• The REAL Reason Your Prostate Is EnlargedKenDBerryMD